Abstract

Eisai Co Ltd is developing the injectable endotoxin antagonist E-5564, for the potential prevention of the pathophysiological effects of endotoxin-mediated responses caused by bacterial infection, including septic shock.

Authors

Ondiveeran HK; Fox-Robichaud A

Journal

IDrugs, Vol. 7, No. 6, pp. 582–590

Publication Date

June 2004

ISSN

1369-7056

Associated Experts

Alison Fox-Robichaud

Professor, Faculty of Health Sciences

Visit profile

Labels

Medical Subject Headings (MeSH)

Animals Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Endotoxemia Endotoxins Humans Lipid A Randomized Controlled Trials as Topic Sepsis Structure-Activity Relationship